Skip to content

3TC treatment preserves and promotes NNRTI resistance

Risk factors for heart disease widespread among HIV patients

Skeletal muscle damage: emerging toxicity of HIV therapy?

Tenofovir/ddI interaction: pancreatitis death highlights risk

Ritonavir highest risk HIV protease inhibitor for lipid rises

Thymidine analogue mutations rare in first-line HAART failure

Once daily fos-amprenavir equal to nelfinavir

How common is lipodystrophy in people who have never taken HIV protease inhibitors?

Lipodystrophy has uneven impact on quality of life, says study